Source: Computer World
The U.S. Food and Drug Administration (FDA) has approved AliveCor to sell technology that will enable and iPhone or Android smartphones to record atrial fibrillation, or AFib, which is the most common form of irregular heartbeat and cardiac arrhythmia.
AliveCor’s Heart Monitor will come as an iPhone case containing two electrodes that can detect a heart rate when gripped by both hands of the user. Through a process called “automated analysis process,” the device can instantly detect if patients are experiencing AFib via real-time electrocardiogram (ECG) recordings taken through the AliveCor Heart Monitor.
“This new technology has great potential to save lives, while also reducing healthcare costs and allow patients as well as their caregivers to make informed decisions about cardiac care,” according to AliveCor CEP Euan Thomson. AFib may have no symptoms, but can lead to congestive heart failure, and the risk of stroke with AFib increases fivefold. This is why such technology will be undoubtedly helpful for many people. Thomson adds, “ …we will incorporate the algorithm in our app and plan to make this available to customers during September.”
The AliveCor Heart Monitor is intended for use by healthcare professionals on patients with known or possible heart issues, and also for those who are health-conscious individuals.